# OncoStem CanAssist Breast

predicts risk of recurrence



Your patient deserves the best. Choose CanAssist Breast - the only prognostic test validated in Indian and Caucasian patients

### What Makes CanAssist Breast Unique?

Validated in India, US, Spain, Germany. Austria,The **Netherlands** Concordance of 83%

with ODX and Mammaprint

# Key Highlights of CAB

Used by patients across India. Middle East

Included in Asian Geriatric Oncology Society guidelines (AGOS)

More Than 95% Negative Predictive Value

# Know the risk of breast cancer recurrence and personalise the treatment through CanAssist Breast

CanAssist Breast (CAB) is India's first Al-driven immunohistochemistry based test, providing crucial insights into breast cancer recurrence risk.

By analyzing key tumor biomarkers, CAB helps oncologists assess whether a patient is at "low-risk" or "high-risk" for recurrence, guiding treatment decisions, including the need for chemotherapy.



#### CanAssist Breast Trusted World Wide

Globally validated across three continents in India, USA, Spain, Germany, Italy, Austria, The Netherlands & Turkey



#### Global Reach of CanAssist Breast Since 2016



From India for the world

#### Patient Testimonials



#### Published In (Latest Publications)



Cureus (Sep 2024)



Breast Cancer Research (Apr 2023)



Cancer Medicine (May 2023)

#### Presented At













## Accredited By







M: +91 96866 96505 T: +91 80 222 400 34

E: info@oncostemdiagnostics.com

W: www.oncostem.com

OncoStem Diagnostics Pvt. Ltd. #4, Raja Ram Mohan Roy Road, Aanand Tower, 2nd Floor, Bangalore - 560027